Based on these encouraging results, two phase III trials are in progress to evaluate the efficacy of zolbetuximab plus chemotherapy as a first-line treatment in patients with CLDN18.2+/HER2-, locally advanced, unresectable, or metastatic G/GEJ adenocarcinoma [125,126]. Here, ERBB2 is linked to gastroesophageal junction adenocarcinoma.